Ventricular assist devices are therapeutic alternatives. Neurosurgical complications of left ventricular assist devices in children.
|
|
- Wesley Chandler
- 5 years ago
- Views:
Transcription
1 J Neurosurg Pediatrics 10: , 2012 Neurosurgical complications of left ventricular assist devices in children Clinical article Rory R. Mayer, B.S., 1 Steven W. Hwang, M.D., 1 Gaddum D. Reddy, M.D., Ph.D., 1 David L. Morales, M.D., 2 William E. Whitehead, M.D., M.P.H., 1 Daniel J. Curry, M.D., 1 Robert J. Bollo, M.D., 1 Thomas G. Luerssen, M.D., 1 and Andrew Jea, M.D. 1 1 Division of Pediatric Neurosurgery, Department of Neurosurgery; and 2 Division of Cardiovascular Surgery, Department of Surgery, Texas Children s Hospital, Baylor College of Medicine, Houston, Texas Object. Left ventricular assist devices (LVADs) are continuous or pulsatile flow devices that could potentially be life-saving measures for patients with end-stage heart failure. These devices have clear advantages over extracorporeal membrane oxygenation (ECMO) and are often used in adults. They are only recently being commonly used in the pediatric age group. As the use of LVADs becomes more mainstream in children, it is important to determine the complication profile associated with these devices. Furthermore, with the increasing application of LVADs in children, pediatric neurosurgeons are seeing a correlative increase in associated neurological complications. In this study, the authors reviewed the incidence of neurological complications due to LVAD use in the pediatric age group and the role of neurosurgery in treatment. Methods. The authors examined data regarding patients with LVADs from the Texas Children s Hospital Heart Center database (July 01, 2007, to June 30, 2011) and recorded neurological complications requiring neurosurgical consultation. They identified 2 children who underwent craniotomies during LVAD treatment. Results. Intracranial hemorrhage occurred in 3 (6.5%) of the 46 patients treated with an LVAD at the authors institution. Of these patients, 2 were treated with craniotomies for life-threatening intracranial hemorrhages. The 3 patients in the neurosurgical cohort presented with cerebral infarction, decreased level of consciousness, and/or seizure. At the last follow-up (286, 503, and 550 days), 1 patient ( 2) had no decline in neurological status, underwent a successful heart transplant, and was discharged home; 1 patient ( 1) died of refractory cardiac failure; and 1 patient ( 3) was on an LVAD for destination therapy (that is, the LVAD is not a bridge to transplantation but rather the final treatment). This patient was discharged from the hospital, but he died of overwhelming fungemia at 286 days while on VAD support. Conclusions. Intracranial hemorrhage is a serious and feared complication of LVAD treatment. While the surgical risk is substantial due to systemic anticoagulation and significant medical comorbidities, neurosurgical evacuation of hemorrhage plays an important life-saving role that can yield successful and acceptable outcomes. ( Key Words complication stroke intracranial hemorrhage left ventricular assist device pediatric neurosurgery Ventricular assist devices are therapeutic alternatives for children who have medically refractory heart failure and are awaiting cardiac transplantation. Ventricular assist devices are pumps that support cardiac output by being connected to either or both ventricles. The pump can be implanted intracorporeally or outside the body and is usually attached to an external battery. The circulatory flow generated by VADs can be either continuous or pulsatile. Even though there has been significant progress with adult VADs, experience and use of the pneumatic pulsatile and continuous flow circulatory Abbreviations used in this paper: ECMO = extracorporeal membrane oxygenation; ICH = intracranial hemorrhage; LVAD = left ventricular assist device; SDH = subdural hematoma. support is still limited in children. 13,24,28 There are several limitations of using these devices directly in children, including small body surface area and problems related to the overall size of the device that often preclude the ability to safely implant intracorporeal devices. Furthermore, decreased stroke volume requirements in children result in an increased risk of thromboembolic events from insufficient washout of VAD pump components. 4,9,29 Until recently, ECMO had been the mainstay of the pediatric circulatory support strategy. 6 Extracorporeal membrane oxygenation differs from a VAD in that it involves cannulation of the venous system (and sometimes the arterial system as well), allowing for extracorporeal oxygenation of the blood. However, the ability of ECMO to bridge children to transplant is quite limited due to increased 370 J Neurosurg: Pediatrics / Volume 10 / November 2012
2 Neurosurgical complications of LVADs in children complications when used for more than 2 weeks, and the use of pulsatile and continuous flow VADs in children has been increasing. Furthermore, some pulsatile VADs have successfully evolved into effective long-term bridges toward heart transplantation. 2 Neurological events and ischemic or hemorrhagic strokes are among the most commonly reported and morbid complications after LVAD placement in adults. 15,18 Patients typically undergo anticoagulation therapy with heparin and occasionally with adjuvant antiplatelet agents. However, there are limited data regarding the risk of neurological complications in children with VADs. Malaisrie et al. 19 described their institutional experience in 8 children. All patients in that study underwent anticoagulation with heparin or warfarin and 1 or more antiplatelet agents; 5 (62.5%) of the 8 patients had postoperative neurological events. In another small study, 10 children underwent bridge to transplantation with pneumatic paracorporeal systems, and 4 suffered neurological events. 3 In contrast, the published European experience has documented a much lower incidence of neurological complications associated with VADs. Hetzer et al. 14 observed only 4 cerebral strokes in 36 patients (11.1%) who survived to undergo either transplantation or device weaning. Moreover, due to the paucity of data regarding neurological complications of VADs in children, there are no clear neurosurgical recommendations to guide management and operative indications for ongoing neurological deficits in this very high risk population that requires continuous anticoagulation and antiplatelet therapy. Many believe that surgery, especially neurosurgery, is ill advised for patients undergoing anticoagulation therapy for VAD support. The purpose of our study was to describe the surgical treatment of patients who underwent craniectomy to evacuate ICHs that developed during LVAD therapy and to discuss associated perioperative management strategies. Methods We retrospectively reviewed the records of 3 consecutive patients who developed ICHs after undergoing LVAD placement (EXCOR, Berlin Heart or HeartMate II, Thoratec) at Texas Children s Heart Center (July 1, 2007, to June 30, 2011), and we cross-referenced them to our neurosurgery database. Patient demographics, neurological complications, details of the operative record, and follow-up reports were extracted and recorded. Of 46 patients in the heart center database, only 3 experienced neurological complications related to LVAD use that required neurosurgical consultation. We were not privy to data for patients with neurological complications who did not require neurosurgical consultation because they are enrolled in a separate investigational study. At the time of this study, LVAD data were sealed and subject to ongoing study for FDA approval. The data collected included patient demographic information, indications for LVAD placement, type of anticoagulation therapy, complications during LVAD use, and neurological and cardiac outcomes. We recorded the neurological complications of LVADs that included CNS hemorrhage as diagnosed on J Neurosurg: Pediatrics / Volume 10 / November 2012 head CT scans, CNS infarction diagnosed on head CT scans, clinically evident seizures, and subclinical seizures seen on electroencephalography only. In addition, the records of 2 patients in our database who underwent craniotomy during LVAD use were identified. Details of the medical and surgical treatment of these patients were recorded. Institutional review board approval was obtained for this study. Results Patient Presentation The mean age of the 3 patients at the time of LVAD placement was 67.0 months (4, 6, and 191 months), and the mean age at the time of neurological complication requiring neurosurgical evaluation was 68.0 months (5, 7, and 192 months); 2 patients were female, and one was male. Two patients had undergone placement of an EX- COR pediatric VAD, and one patient received a Heart- Mate II VAD (Table 1). The mean interval between LVAD implantation and clinical presentation of intracranial pathology was 23.7 days (range days). Signs and symptoms of neurological complications included seizures, decreased interactive play, and decreased responsiveness. All patients seen by neurosurgeons in this series presented with ICH. All 3 patients had SDHs, and 1 patient also had an intraparenchymal hemorrhage and ischemic stroke. Seizures were documented in 1 patient (Table 2). Medical Management at the Time of Complication The 3 patients who experienced intracranial hemorrhagic complications were taking therapeutic doses of heparin; 1 was also taking aspirin. In the 2 patients who required operative intervention because of deteriorating neurological examination findings, anticoagulation was fully reversed in one patient ( 2) and discontinued but not reversed in the other ( 3). Prothrombin time and activated partial thromboplastin time were optimized using fresh frozen plasma and vitamin K for surgery. Postoperatively, daily platelet transfusions were administered to maintain a level higher than /L. Cryoprecipitate infusions were ordered for fibrinogen counts of less than 150 mg/dl. Daily postoperative laboratory examinations included lactate dehydrogenase and plasma hemoglobin to monitor for signs of intrapump thrombus formation. After craniotomy, one patient ( 2) restarted anticoagulation therapy 72 hours after surgery. The other surgically treated patient ( 3) restarted anticoagulation therapy 6 days after surgery. Surgical Treatment One patient ( 1) was managed conservatively due to mild symptoms and stable imaging findings. The other 2 patients in our series underwent craniotomies, and surgical complications occurred in both. A right-sided craniotomy with evacuation was performed in 1 patient ( 2) who had an acute right SDH, causing a decreased level of consciousness and left hemiparesis (Fig. 1). This patient developed evidence of a perioperative ischemic stroke in the left occipital lobe of 371
3 R. R. Mayer et al. TABLE 1: Demographics of LVAD-treated patients requiring neurosurgical consultation No. Age at LVAD Placement (mos) Age at Complication (mos) Sex Reason for VAD Type of VAD Type of Anticoagulation F dilated cardiomyopathy EXCOR heparin F dilated cardiomyopathy EXCOR heparin M transposition of great vessels HeartMate II heparin, aspirin presumed embolic origin from the LVAD in the setting of withheld anticoagulation during neurosurgery. This patient also developed a pseudomeningocele that required further sur gical management for resolution. The other patient ( 3) who underwent a craniotomy developed herniation syndrome with a dilated left pupil and decreased responsiveness after an initial seizure and subsequently underwent a left hemicraniectomy (Fig. 2). The postoperative CT scan still showed residual midline shift as well as reaccumulation of blood in the subdural space. The patient was returned to the operating room for evacuation of the recurrent SDH (Table 3). Outcomes Patients were assessed at the last follow-up (286, 503, and 550 days) for neurological and cardiac outcomes. The patient who did not undergo a neurosurgical procedure ( 1) underwent a transplant and was discharged home but died 11 months posttransplantation of graft failure. Of the patients who underwent emergency neurosurgical intervention, 1 patient ( 2) was neurologically intact, received a heart transplant at 87 days after SDH evacuation, and remains stable at 19 months posttransplantation. The other patient ( 3) maintained a residual right hemiparesis from his initial neurological insult. This patient had an LVAD as a bridge to destination and was discharged from the hospital. He subsequently died of fungal sepsis 286 days after SDH evacuation. Both patients who underwent neurosurgical procedures remained stable with anticoagulation while on LVAD support (Table 4). Illustrative 2 This female patient developed dilated cardiomyopathy and subsequent heart failure shortly after birth. The patient underwent placement of an EXCOR pediatric VAD at 4 months of age. During the postoperative period, she was maintained on heparin anticoagulation for her VAD. At 1 month postoperation, the patient was noted to have decreased responsiveness and a left hemiparesis. A CT scan of the head demonstrated a right-sided SDH with 9 mm of midline shift (Fig. 1). The scan demonstrated components of acute and chronic bleeding. The patient underwent an emergency right-sided craniotomy with evacuation of the hematoma. Postoperative imaging demonstrated a left occipital ischemic stroke that was not present on prior imaging. Postoperatively, the patient developed a pseudomeningocele requiring dural repair and later revision; it slowly improved over time. At 87 days after SDH evacuation, she received a heart transplant, and the LVAD was discontinued. On last follow-up, approximately 1.5 years after neurosurgical intervention, the patient was meeting neurological milestones and was stable from a cardiac standpoint. Discussion Mechanical support as a bridge to heart transplantation improves survival in children with end-stage heart failure. 11,12 Extracorporeal membrane oxygenation remains the most common type of mechanical support used in the pediatric age group, especially for acute forms of heart failure. 8,12,21 However, ECMO nonpulsatile flow restricts patient mobility and presents a high incidence of hemorrhagic and infective complications when used for more than 2 weeks, and thus is not an effective bridge to transplantation. 17 The use of pulsatile, paracorporeal, closed-circuit VADs extends support time and influences management TABLE 2: Summary of clinical presentations of VAD-treated patients with neurosurgical complications No. Signs & Symptoms Neurological Complication 1 decreased interactive play intraparenchymal hemorrhage & infarction transformed into chronic subdural hygroma/hematoma 2 decreased responsiveness SDH 3 seizure SDH Fig Left: Preoperative brain CT scan without contrast showing a 10-mm-thick acute right-sided SDH with hyperacute findings and 8.2 mm of right-to-left midline shift. Right: Brain CT scan without contrast obtained at 4 months after surgery, demonstrating no acute intracranial pathology; however, there is the formation of a large subgaleal pseudomeningocele. 372 J Neurosurg: Pediatrics / Volume 10 / November 2012
4 Neurosurgical complications of LVADs in children TABLE 4: Outcome summary of all patients with neurological complications during VAD use No. Cardiac Outcome Neurological Outcome Follow-Up (days) 1 bridge to trans- died 503 plant, then heart failure 2 stable meeting neurological 550 milestones 3 fungemia of LVAD, sepsis rt hemiparesis, died 286 Fig A: Brain CT scan obtained preoperatively without contrast, demonstrating a thin acute left-sided SDH; however, there is 6.6 mm of left-to-right midline shift. B: Brain CT scan without contrast obtained immediately postoperatively, showing a reaccumulation of the extraaxial hematoma with interhemispheric extension and worsening midline shift (now measuring 15.6 mm). C: Brain CT scan without contrast obtained postoperatively after the second procedure to evacuate the reaccumulated subdural blood, showing resolution of the midline shift with stable subdural, intraparenchymal, and intraventricular hematoma. D: Brain CT scan without contrast obtained 8 months after surgery, just prior to death, demonstrating no acute intracranial pathology with ex vacuo changes related to the left lateral ventricle. of end-stage heart failure in the pediatric population. 1,7,23 Pulsatile pumping results in better tissue perfusion and an increased recruitment of the microcirculation of the brain, lungs, and kidneys. 2 In addition, by reversing endorgan dysfunction, pulsatile VADs improve the overall clinical condition and the likelihood of successful heart transplantation. 5,14,22,28 Continuous flow VADs (such as the HeartMate II) now provide an additional method of mechanical support prior to transplantation in the pediatric population. 20 Furthermore, the US FDA recently approved the EXCOR Pediatric System (Berlin Heart), TABLE 3: Surgical complications after craniotomy or craniectomy for ICH in 2 patients with LVADs No. Indication Neurosurgical Op Intraop Complications 2 rt SDH rt craniotomy lt occipital ischemic stroke 3 lt SDH lt hemicrani- none ectomy Postoperative Complications pseudomeningocele secondary herniation, recurrent lt SDH, death* * SDH required reoperation within the 24-hour postoperative period. J Neurosurg: Pediatrics / Volume 10 / November 2012 which was found to successfully bridge 90% of children to heart transplantation, a significant improvement when compared with the use of ECMO. 30 However, as our small series demonstrates, the use of VADs is not without serious neurological complications. To the best of our knowledge, this is the first study to describe the neurosurgical management of acute, severe neurological complications following VAD implantation. Our institutional experience, consistent with several recent studies, demonstrates that these complications represent an important and emerging group of complications in pediatric patients. 2,5,19 The overall incidence of ICH was 6.5% of the total cohort of 46 patients, with 2 of 3 patients presenting with ICH requiring operative treatment. We found that the rate of neurological complications and, in particular, hemorrhage was similar in children compared with adults (2.5% 10%). 16,18,20 In contrast to children, a large percentage of adult patients with LVADs have a history of stroke prior to implantation, a risk factor for later stroke recurrence. 18 The rate of mortality from mechanical circulatory support in adults increases from 61% in those without ICH to 92.3% in those with ICH; 20 however, the role of surgically evacuating ICH in these patients is not clear. Our study documents short- and long-term results of craniotomy/craniectomy for symptomatic ICH during LVAD placement in children. Each of the 2 children who were surgically treated at our institution had an ICH during LVAD use. Of the 2 patients who underwent craniotomy/ craniectomy, one patient ( 3) remained on LVAD and had the heparin anticoagulation temporarily halted, but not reversed, during the procedure. The other patient ( 2) remained on LVAD, but had the anticoagulation fully reversed for the procedure. There is no evidence-based approach to manage ICH in LVAD-treated patients. In our experience, the recommended approach begins with an immediate reversal of anticoagulation and antiplatelet therapy. The target goal is to obtain a full reversal of the prothrombin time and activated partial thromboplastin time and maintain the platelet count higher than /L; however, we recommend a modulation of these targets, depending on the extent of bleeding and type of VAD. As an example, the HeartMate II is designed with a biological surface derived from fibrin and does not require long-term anticoagulation (except aspirin); 25 therefore, we are less care- 373
5 R. R. Mayer et al. ful in regard to a full reversal of anticoagulation with the HeartMate II than we are with the EXCOR device. Infusions of fresh frozen plasma, cryoprecipitate, factor VII, protamine, platelets, desmopressin, and/or vitamin K are given, depending on the specific therapy the patient is receiving. Intraoperatively, these patients often require vigorous blood pressure support and fluid resuscitation. 10 Postoperatively, daily laboratory values should include lactate dehydrogenase and plasma hemoglobin to monitor for signs of intrapump thrombus formation and hemolysis. The LVAD cardiac output and pump parameters can be manipulated to decrease the probability of clot formation during this period of low or no anticoagulation by increasing the rate and ensuring full ejection. We recommend a consultation with the hematology service to optimize coagulation parameters in the postoperative period. In our series, both surgically treated patients restarted heparin anticoagulation therapy more than 72 hours after surgery. The decision to intervene surgically in these high-risk patients is difficult. Our results demonstrate that the risk of perioperative neurological complication is high, given the necessity to modify anticoagulation parameters during surgery, but good intermediate neurological outcomes are attainable. All 3 patients whom we treated had good intermediate neurological follow-up. While one patient who underwent surgical intervention died of fungemia approximately 9 months after surgery, the other patient who underwent craniotomy went on to receive a heart transplant and, from a cardiac and neurological standpoint, is doing well. Acceptable long-term outcomes depend not only on neurological recovery but also on a good cardiovascular prognosis. Future research will determine at which point the risk of hemorrhage is reduced enough to permit safe treatment with traditional anticoagulants and whether new approaches to anticoagulation might be suitable in the acute stroke and poststroke periods. 26,27 Conclusions Intracranial hemorrhage is a significant complication of the emerging therapy of LVADs in children with heart failure. The incidence of LVAD-associated ICH in children appears similar when compared with that in adults. Neurosurgical intervention may be considered for select patients with LVAD-associated ICH. Disclosure The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. Author contributions to the study and manuscript preparation include the following. Conception and design: Jea. Acquisition of data: Jea. Analysis and interpretation of data: Jea. Drafting the article: Jea, Mayer, Hwang. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Jea. Administrative/technical/material support: Jea. Study supervision: Jea. References 1. Adachi I, Fraser CD Jr: Mechanical circulatory support for infants and small children. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 14:38 44, Amodeo A, Brancaccio G, Michielon G, Filippelli S, Ricci Z, Morelli S, et al: Pneumatic pulsatile ventricular assist device as a bridge to heart transplantation in pediatric patients. Artif Organs 34: , Arabía FA, Tsau PH, Smith RG, Nolan PE, Paramesh V, Bose RK, et al: Pediatric bridge to heart transplantation: application of the Berlin Heart, Medos and Thoratec ventricular assist devices. J Heart Lung Transplant 25:16 21, Ashton RC Jr, Oz MC, Michler RE, Champsaur G, Catanese KA, Hsu DT, et al: Left ventricular assist device options in pediatric patients. ASAIO J 41:M277 M280, Cassidy J, Haynes S, Kirk R, Crossland D, Smith JH, Hamilton L, et al: Changing patterns of bridging to heart transplantation in children. J Heart Lung Transplant 28: , Chang AC, McKenzie ED: Mechanical cardiopulmonary support in children and young adults: extracorporeal membrane oxygenation, ventricular assist devices, and long-term support devices. Pediatr Cardiol 26:2 28, Davies RR, Russo MJ, Hong KN, O Byrne ML, Cork DP, Moskowitz AJ, et al: The use of mechanical circulatory support as a bridge to transplantation in pediatric patients: an anal ysis of the United Network for Organ Sharing database. J Tho rac Cardiovasc Surg 135: , del Nido PJ, Armitage JM, Fricker FJ, Shaver M, Cipriani L, Dayal G, et al: Extracorporeal membrane oxygenation support as a bridge to pediatric heart transplantation. Circulation 90: II66 II69, Duncan BW: Mechanical circulatory support for infants and children with cardiac disease. Ann Thorac Surg 73: , Factora FN, Bustamante S, Spiotta A, Avitsian R: Intracranial hemorrhage surgery on patients on mechanical circulatory support: a case series. J Neurosurg Anesthesiol 23:30 34, Garcia-Guereta L, Cabo J, de la Oliva P, Villar MA, Bronte LD, Goldman L, et al: Ventricular assist device application with the intermediate use of a membrane oxygenator as a bridge to pediatric heart transplantation. J Heart Lung T r a n s p l a nt 28: , Goldman AP, Cassidy J, de Leval M, Haynes S, Brown K, Whitmore P, et al: The waiting game: bridging to paediatric heart transplantation. Lancet 362: , Hetzer R, Loebe M, Potapov EV, Weng Y, Stiller B, Hennig E, et al: Circulatory support with pneumatic paracorporeal ventricular assist device in infants and children. Ann Thorac Surg 66: , Hetzer R, Potapov EV, Stiller B, Weng Y, Hübler M, Lemmer J, et al: Improvement in survival after mechanical circulatory support with pneumatic pulsatile ventricular assist devices in pediatric patients. Ann Thorac Surg 82: , Holman WL, Bourge RC, Spruell RD, Murrah CP, McGiffin DC, Kirklin JK: Ventricular assist devices as a bridge to cardiac transplantation. A prelude to destination therapy. Ann Surg 225: , Humpl T, Furness S, Gruenwald C, Hyslop C, Van Arsdell G: The Berlin Heart EXCOR Pediatrics The SickKids Experience Artif Organs 34: , Ibrahim AE, Duncan BW, Blume ED, Jonas RA: Long-term follow-up of pediatric cardiac patients requiring mechanical circulatory support. Ann Thorac Surg 69: , Lazar RM, Shapiro PA, Jaski BE, Parides MK, Bourge RC, Watson JT, et al: Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment 374 J Neurosurg: Pediatrics / Volume 10 / November 2012
6 Neurosurgical complications of LVADs in children of Congestive Heart Failure (REMATCH) experience. Circulation 109: , Malaisrie SC, Pelletier MP, Yun JJ, Sharma K, Timek TA, Rosenthal DN, et al: Pneumatic paracorporeal ventricular assist device in infants and children: initial Stanford experience. J Heart Lung Transplant 27: , Owens WR, Bryant R III, Dreyer WJ, Price JF, Morales DL: Initial clinical experience with the HeartMate II ventricular assist system in a pediatric institution. Artif Organs 34: , Pollock JC, Charlton MC, Williams WG, Edmonds JF, Trusler GA: Intraaortic balloon pumping in children. Ann Thorac Surg 29: , Potapov EV, Stiller B, Hetzer R: Ventricular assist devices in children: current achievements and future perspectives. Pediatr Transplant 11: , Reinhartz O, Keith FM, El-Banayosy A, McBride LR, Robbins RC, Copeland JG, et al: Multicenter experience with the thoratec ventricular assist device in children and adolescents. J Heart Lung Transplant 20: , Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al: Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345: , Samuels LE, Kohout J, Casanova-Ghosh E, Hagan K, Garwood P, Ferdinand F, et al: Argatroban as a primary or secondary postoperative anticoagulant in patients implanted with ventricular assist devices. Ann Thorac Surg 85: , Spanier T, Oz M, Levin H, Weinberg A, Stamatis K, Stern D, et al: Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiovasc Surg 112: , Spanier TB, Chen JM, Oz MC, Stern DM, Rose EA, Schmidt AM: Time-dependent cellular population of textured-surface left ventricular assist devices contributes to the development of a biphasic systemic procoagulant response. J Thorac Cardiovasc Surg 118: , Stiller B, Weng Y, Hübler M, Lemmer J, Nagdyman N, Redlin M, et al: Pneumatic pulsatile ventricular assist devices in children under 1 year of age. Eur J Cardiothorac Surg 28: , Tschirkov A, Nikolov D, Papantchev V: The Berlin Heart EX- COR in an 11-year-old boy: a bridge to recovery after myocardial infarction. Tex Heart Inst J 34: , US Food and Drug Administration: FDA approves mechanical cardiac assist device for children with heart failure. ( ments/ucm htm) [Accessed August 3, 2012] Manuscript submitted March 22, Accepted July 31, Please include this information when citing this paper: published online August 31, 2012; DOI: / PEDS Address correspondence to: Andrew Jea, M.D., Division of Pediatric Neurosurgery, Texas Children s Hospital, 6621 Fannin Street, CCC , 12th Floor, Houston, Texas ahjea@ texaschildrenshospital.org. J Neurosurg: Pediatrics / Volume 10 / November
Pediatric Mechanical Circulatory Support (MCS)
Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children s Hospital Medical Center The University of Cincinnati
More informationWhy Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support
Why Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support Utpal S Bhalala, MD, FAAP Assistant Professor and Director of Research Pediatric Critical Care
More informationHeart failure affects approximately 6 million people. Management of intracranial hemorrhage in patients with left ventricular assist devices
J Neurosurg 118:1063 1068, 2013 AANS, 2013 Management of intracranial hemorrhage in patients with left ventricular assist devices Clinical article Thomas J. Wilson, M.D., William R. Stetler Jr., M.D.,
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
More informationLeft Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
More informationMechanical Ventricular Circulatory Support in Children; Bad Oeynhausen Experience
Original Article Mechanical Ventricular Circulatory Support in Children; Bad Oeynhausen Experience Kazutomo Minami, MD, PhD, 1 Edzard von Knyphausen, MD, 2 Ryusuke Suzuki, MD, 1 Ute Blanz, MD, 1 Latif
More informationUnderstanding the Pediatric Ventricular Assist Device
Understanding the Pediatric Ventricular Assist Device W. James Parks, MSc., MD Pediatric Cardiologist Assistant Professor of Pediatrics and Radiology Children s Healthcare of Atlanta Sibley Heart Center
More informationFirst Experiences With the HeartWare Ventricular Assist System in Children
First Experiences With the HeartWare Ventricular Assist System in Children Oliver Miera, MD, Evgenij V. Potapov, MD, PhD, Matthias Redlin, MD, Alexander Stepanenko, MD, Felix Berger, MD, PhD, Roland Hetzer,
More informationLVAD Complications, Recovery
LVAD Complications, Recovery Abbas Ardehali, M.D., F.A.C.S. Professor of Surgery and Medicine, Division of Cardiac Surgery William E. Connor Chair in Cardiothoracic Transplantation Director, UCLA Heart,
More informationEvaluation of Native Left Ventricular Function During Mechanical Circulatory Support.: Theoretical Basis and Clinical Limitations
Review Evaluation of Native Left Ventricular Function During Mechanical Circulatory Support.: Theoretical Basis and Clinical Limitations Tohru Sakamoto, MD, PhD Left ventricular function on patients with
More informationComplications of Left Ventricular Assist Device Chronic Support. Dr. Tal Hasin RMC, Beilinson, Petach-Tiqva, Israel
Complications of Left Ventricular Assist Device Chronic Support. Dr. Tal Hasin RMC, Beilinson, Petach-Tiqva, Israel No disclosures Probability of survival Survival (%) Survival with LVAD Destination Bridge
More informationAllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
More informationMEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES
MEDICAL POLICY PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts
Implantable Ventricular Assist Devices and Total Artificial Hearts Policy Number: Original Effective Date: MM.06.017 05/21/1999 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
More informationA thesis submitted to the. Graduate School. of the University of Cincinnati. in partial fulfillment of the. requirements for the degree of
Virtual Implantation Of Mechanical Circulatory Support Devices A thesis submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements for the degree of Master
More informationMechanical Support in the Failing Fontan-Kreutzer
Mechanical Support in the Failing Fontan-Kreutzer Stephanie Fuller MD, MS Thomas L. Spray Endowed Chair in Congenital Heart Surgery Associate Professor, The Perelman School of Medicine at the University
More informationModern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies
Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies ERIC T. ROME D.O. HEART FAILURE, MECHANICAL ASSISTANCE AND TRANSPLANTATION CVI Left Ventricular Assist Device An
More informationConcomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis
Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis April 11, 2014 Jason O. Robertson, M.D., M.S.; David C. Naftel, Ph.D., Sunil
More informationRecombinant Factor VIIa for Intracerebral Hemorrhage
Recombinant Factor VIIa for Intracerebral Hemorrhage January 24, 2006 Justin Lee Pharmacy Resident University Health Network Outline 1. Introduction to patient case 2. Overview of intracerebral hemorrhage
More informationMultiple case reports of successful use, with only one case report of intra device thrombotic event
rfviia in VAD Patients Limited data exist regarding safety Multiple factors increase pro thrombotic potential Multiple case reports of successful use, with only one case report of intra device thrombotic
More informationJapanese Multicenter Outcomes With the HeartMate II Left Ventricular Assist Device in Patients With Small Body Surface Area
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Advance Publication by-j-stage Japanese Multicenter Outcomes With the HeartMate II Left Ventricular Assist
More informationJapanese Multicenter Outcomes With the HeartMate II Left Ventricular Assist Device in Patients With Small Body Surface Area
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Cardiovascular Surgery Japanese Multicenter Outcomes With the HeartMate II Left Ventricular
More informationJennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio
Biventricular Heart Failure Advanced Treatment Options at The Cleveland Clinic Jennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio I have no disclosures. Examine respiratory and
More informationPediatric Mechanical Circulatory Support - What to Use
Pediatric Mechanical Circulatory Support - What to Use Ronald K. Woods, MD, PhD Associate Professor Medical College of Wisconsin Pediatric Cardiothoracic Surgery Children s Hospital of Wisconsin Disclosure
More informationBerlin Heart Pediatric Assistance Device: The Beginnings, The Teachings And The Cruising Speed : A Monocentric Experience With The Same System
Berlin Heart Pediatric Assistance Device: The Beginnings, The Teachings And The Cruising Speed : A Monocentric Experience With The Same System Roland Henaine, Mathieu Vergnat, Geoffray Keller, Magali Veyrier,
More informationORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 48 (2015) 158 162 doi:10.1093/ejcts/ezu406 Advance Access publication 29 October 2014 ORIGINAL ARTICLE Cite this article as: Bernhardt AM, De By TMMH, Reichenspurner
More informationJournal of the American College of Cardiology Vol. 60, No. 1, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 60, No. 1, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.031
More informationHeart Transplantation is Dead
Heart Transplantation is Dead Alternatives to Transplantation in Heart Failure Sagar Damle, MD University of Colorado Health Sciences Center Grand Rounds September 8, 2008 Outline Why is there a debate?
More informationFrom Recovery to Transplant: One Patient's Journey
From Recovery to Transplant: One Patient's Journey Tonya Elliott, RN, MSN Assist Device and Thoracic Transplant Coordinator Inova Transplant Center at Inova Fairfax Hospital Falls Church, VA Introduction
More informationVAD come Destination therapy nell adulto con Scompenso Cardiaco
VAD come Destination therapy nell adulto con Scompenso Cardiaco Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova Medical School, Italy Heart Transplantation is
More informationThe Gold Standard in Pediatric VAD Therapy A Compilation of Publications Demonstrating the Clinical Excellence of EXCOR Pediatric
EXCOR Pediatric The Gold Standard in Pediatric VAD Therapy A Compilation of Publications Demonstrating the Clinical Excellence of EXCOR Pediatric EXCOR Pediatric The Gold Standard in Pediatric VAD Therapy
More informationExtracorporeal life support in preoperative and postoperative heart transplant management
Review Article Page 1 of 6 Extracorporeal life support in preoperative and postoperative heart transplant management Christian A. Bermudez 1, D. Michael McMullan 2 1 Division of Cardiovascular Surgery,
More informationPercutaneous Cardiopulmonary Support after Acute Myocardial Infarction at the Left Main Trunk
Original Article Percutaneous Cardiopulmonary Support after Acute Myocardial Infarction at the Left Main Trunk Takashi Yamauchi, MD, PhD, 1 Takafumi Masai, MD, PhD, 1 Koji Takeda, MD, 1 Satoshi Kainuma,
More informationSPECIAL FEATURE.
http://www.jhltonline.org SPECIAL FEATURE Bridging children of all sizes to cardiac transplantation: The initial multicenter North American experience with the Berlin Heart EXCOR ventricular assist device
More informationOutpatient Treatment of MCS Patient. F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA
Outpatient Treatment of MCS Patient F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA Disclosure Statement I DO NOT HAVE ANY RELEVANT FINANCIAL RELATIONSHIPS WITH ANY COMMERCIAL
More informationAndrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
More informationRisk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Relevant Financial Relationship
More informationMechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
More informationCASE PRESENTATION Ravi Dhanisetty, M.D. SUNY Downstate 23 July 2009 CASE PRESENTATION xx yr old female with chest pain for 3 days. Initially taken to outside hospital 3 days history of chest pain, shortness
More informationReversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support
http://www.jhltonline.org Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support Guillermo Torre-Amione, MD, PhD, a Robert E. Southard, MD, b Matthias M. Loebe,
More informationVentricular Assist Device in Pediatric Heart Failure 성균관의대삼성서울병원흉부외과학교실
Ventricular Assist Device in Pediatric Heart Failure 양지혁 성균관의대삼성서울병원흉부외과학교실 순서 서론왜 VAD 가필요한가? 말기심부전치료의현황 ECMO vs. VAD 심근회복에대한기계순환보조의효과 어떤환자에서 VAD 를사용할것인가? 어떤 VAD 를사용할것인가? 결론 Introduction Ventricular Assist
More informationMEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationAdverse Event. Adverse Event Status. Please enter the date of the event you are reporting: Please enter a label describing this event:
Adverse Event Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 17 Adverse Event Infection Was there a major infection? Date of
More informationA Fully Magnetically Levitated Left Ventricular Assist Device. Final Report of the MOMENTUM 3 Trial
A Fully Magnetically Levitated Left Ventricular Assist Device Final Report of the MOMENTUM 3 Trial Mandeep R. Mehra, MD, Nir Uriel, MD, Joseph C. Cleveland, Jr., MD, Daniel J. Goldstein, MD, National Principal
More informationHEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM
HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM A New Milestone in LVAD Therapy HeartMate 3 Left Ventricular Assist Device Introducing the new HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY HeartMate 3 LVAD
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts
Implantable Ventricular Assist Devices and Total Artificial Hearts Policy Number: Original Effective Date: MM.06.017 05/21/1999 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
More informationTHE USE of VENTRICULAR ASSIST DEVICES in CHILDREN: CURRENT OPTIONS & FUTURE TRENDS
THE USE of VENTRICULAR ASSIST DEVICES in CHILDREN: CURRENT OPTIONS & FUTURE TRENDS ADULTS : VAD Better Accepted Technically easier Fewer anatomical constraints HTx is realistic possibility Overall experience
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts
Implantable Ventricular Assist Devices and Total Artificial Hearts Policy Number: Original Effective Date: MM.06.017 05/21/1999 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
More informationECMO as a Bridge to Heart Transplant in the Era of LVAD s.
Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania ECMO as a Bridge to Heart Transplant in the Era of
More informationECMO CPR. Ravi R. Thiagarajan MBBS, MPH. Cardiac Intensive Care Unit
ECMO CPR Ravi R. Thiagarajan MBBS, MPH Staff Intensivist Cardiac Intensive Care Unit Children s Hospital Boston PCICS 2008, Miami, FL No disclosures Disclosures Outline Outcomes for Pediatric in-hospital
More informationDestination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT.
DT Destination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT. ONLY WE HAVE THIS BREADTH OF CLINICAL EVIDENCE TO SUPPORT DESTINATION THERAPY.
More informationMechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
More informationLIVING A MORE ACTIVE LIFE. with the HeartMate 3 LVAD for the treatment of advanced heart failure RON. Recipient
LIVING A MORE ACTIVE LIFE with the HeartMate 3 LVAD for the treatment of advanced heart failure RON HeartMate 3 LVAD Recipient What is HEART FAILURE? Heart failure sometimes called a weak heart occurs
More informationTo ECMO Or Not To ECMO Challenges of venous arterial ECMO. Dr Emily Granger St Vincent s Hospital Darlinghurst NSW
To ECMO Or Not To ECMO Challenges of venous arterial ECMO Dr Emily Granger St Vincent s Hospital Darlinghurst NSW The Start: 1972 St Vincent s Hospital The Turning Point ECMO program restarted in 2004
More informationTotal Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Policy Number: 7.03.11 Last Review: 12/2018 Origination: 12/2001 Next Review: 12/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationLow thromboembolic risk for patients with the Heartmate II left ventricular assist device
Evolving Technology John et al Low thromboembolic risk for patients with the Heartmate II left ventricular assist device Ranjit John, MD, a Forum Kamdar, BS, a Kenneth Liao, MD, a Monica Colvin Adams,
More informationUpdate on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada
Update on Mechanical Circulatory Support AATS May 5, 2010 Toronto, ON Canada Disclosures NONE Emergency Circulatory Support ECMO Tandem Heart Impella Assessment Cardiac Function Pulmonary function Valvular
More informationIntra-operative Effects of Cardiac Surgery Influence on Post-operative care. Richard A Perryman
Intra-operative Effects of Cardiac Surgery Influence on Post-operative care Richard A Perryman Intra-operative Effects of Cardiac Surgery Cardiopulmonary Bypass Hypothermia Cannulation events Myocardial
More informationExtracorporeal Membrane Oxygenation (ECMO)
Extracorporeal Membrane Oxygenation (ECMO) Policy Number: Original Effective Date: MM.12.006 05/16/2006 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 11/01/2014 Section: Other/Miscellaneous
More informationMedical Policy. MP Total Artificial Hearts and Implantable Ventricular Assist Devices
Medical Policy MP 7.03.11 BCBSA Ref. Policy: 7.03.11 Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery Related Policies 7.03.08 Heart/Lung Transplant 7.03.09 Heart Transplant 8.01.60
More informationECMO Primer A View to the Future
ECMO Primer A View to the Future Todd J. Kilbaugh Assistant Professor of Anesthesiology, Critical Care Medicine, and Pediatrics Director of The ECMO Center at the Children s Hospital of Philadelphia Disclosures
More informationExtra Corporeal Life Support for Acute Heart failure
Extra Corporeal Life Support for Acute Heart failure Benjamin Medalion, MD Director Heart and Lung Transplantation Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Campus, Israel Mechanical
More informationMulti-targeted Antithrombotic Therapy for Total Artificial Heart Device Patients: a case series
Multi-targeted Antithrombotic Therapy for Total Artificial Heart Device Patients: a case series Angeleah Ramirez BS 1 Jeff Riley CCP Lyle Joyce MD 1. Second year perfusion student - Midwestern University
More informationHEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU
HEARTMATE 3 WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU HEARTMATE 3 with Full MagLev Flow Technology HEARTMATE 3 DELIVERS UNPRECEDENTED * SURVIVAL AND SAFETY OUTCOMES **1 LANDMARK SURVIVAL
More informationTotal Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Policy Number: 7.03.11 Last Review: 12/2017 Origination: 12/2001 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City
More informationCardiopulmonary Support and Physiology. Prediction of cardiac function after weaning from ventricular assist devices
Liang et al Cardiopulmonary Support and Physiology Prediction of cardiac function after weaning from ventricular assist devices Hong Liang, MD, a Hansheng Lin, MD, b Yuguo Weng, MD, c Michael Dandel, MD,
More informationEMS: Care of the VAD Patient. Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI
EMS: Care of the VAD Patient Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI Disclosure No relevant financial relationships by planners or presenters Left Ventricular Assist
More informationIs it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)?
Is it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)? A treatment for advanced heart failure. LAURA HeartMate II LVAD Recipient What is HEART FAILURE? Heart failure sometimes called
More informationPRACTICE GUIDELINE. DEFINITIONS: Mild head injury: Glasgow Coma Scale* (GCS) score Moderate head injury: GCS 9-12 Severe head injury: GCS 3-8
PRACTICE GUIDELINE Effective Date: 9-1-2012 Manual Reference: Deaconess Trauma Services TITLE: TRAUMATIC BRAIN INJURY GUIDELINE OBJECTIVE: To provide practice management guidelines for traumatic brain
More informationLEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS. Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus
LEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus OBJECTIVES Review the most common LVAD-related complications.
More informationSurgical Options for Advanced Heart Failure
Surgical Options for Advanced Heart Failure Benjamin Medalion, MD Director, Transplantation and Heart Failure Surgery Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Hospital Heart
More informationVentricular assist devices (VADs) have become an
IMPORTANCE OF PREOPERATIVE LIVER FUNCTION AS A PREDICTOR OF SURVIVAL IN PATIENTS SUPPORTED WITH THORATEC VENTRICULAR ASSIST DEVICES AS A BRIDGE TO TRANSPLANTATION Olaf Reinhartz, MD David J. Farrar, PhD
More informationECMO vs. CPB for Intraoperative Support: How do you Choose?
ECMO vs. CPB for Intraoperative Support: How do you Choose? Shaf Keshavjee MD MSc FRCSC FACS Director, Toronto Lung Transplant Program Surgeon-in-Chief, University Health Network James Wallace McCutcheon
More informationEcho assessment of patients with an ECMO device
Echo assessment of patients with an ECMO device Evangelos Leontiadis Cardiologist 1st Cardiology Dept. Onassis Cardiac Surgery Center Athens, Greece Gibbon HLM 1953 Goldstein DJ et al, NEJM 1998; 339:1522
More informationMechanical assist patient selection, device selection, and outcomes
Mechanical assist patient selection, device selection, and outcomes Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine
More informationSuccessful Clot Retrieval Therapy of Cerebral Embolism in a Pediatric Patient with Ventricular Assist Device: A Case Report
Journal of Neuroendovascular Therapy 2017; 11: 29 34 Online November 9, 2016 DOI: 10.5797/jnet.cr.2016-0063 Successful Clot Retrieval Therapy of Cerebral Embolism in a Pediatric Patient with Ventricular
More informationInitial experience with Imacor htee-guided management of patients following transplant and mechanical circulatory support.
Thomas Jefferson University Jefferson Digital Commons Department of Cancer Biology Faculty Papers Department of Cancer Biology Fall 11-1-2012 Initial experience with Imacor htee-guided management of patients
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationVTE in Children: Practical Issues
VTE in Children: Practical Issues Wasil Jastaniah MBBS,FAAP,FRCPC Consultant Pediatric Hem/Onc/BMT May 2012 Top 10 Reasons Why Pediatric VTE is Different 1. Social, ethical, and legal implications. 2.
More informationImproving Outcomes in Patients With Ventricular Assist Devices Transferred From Outlying to Tertiary Care Hospitals
The Journal of The American Society of Extra-Corporeal Technology Improving Outcomes in Patients With Ventricular Assist Devices Transferred From Outlying to Tertiary Care Hospitals Mark B. Anderson, MD;*
More informationVentricular Assist Device. Lauren Bartlett 10/5/16 BME 281, section 1
Ventricular Assist Device Lauren Bartlett 10/5/16 BME 281, section 1 What is a Ventricular Assist Device (VAD)? Electromechanical device for assisting cardiac circulation Used to partially or completely
More informationCABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin
CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin DISCLOSURES None Objective(s): Our department routinely used
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Total Artificial Hearts and Ventricular Assist Devices Page 1 of 39 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Total Artificial Hearts and Ventricular Assist
More informationInferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski. Department of Surgery Grand Rounds March 24, 2008
Inferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski Department of Surgery Grand Rounds March 24, 2008 History of Vena Cava Filters Virchow-1846-Proposes PE originate from veins
More informationManagement of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist
Dr Stephen Pettit, Consultant Cardiologist Cardiogenic shock Management of Cardiogenic Shock Outline Definition, INTERMACS classification Medical management of cardiogenic shock PA catheters and haemodynamic
More informationDescription. Section: Surgery Effective Date: April 15, Subsection: Transplant Original Policy Date: September 13, 2012 Subject:
Last Review Status/Date: March 2016 Page: 1 of 30 Description Mechanical devices to assist or replace a failing heart have been developed over many decades of research. A ventricular assist device (VAD)
More informationHeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update
HeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update Mark S. Slaughter, MD University of Louisville, KY, USA HeartWare Users Meeting 29 October 2012 Barcelona, Spain HEARTWARE,
More informationPaediatric mechanical circulatory support with Berlin Heart EXCOR: development and outcome of a 23-year experience
European Journal of Cardio-Thoracic Surgery 50 (2016) 203 210 doi:10.1093/ejcts/ezw011 Advance Access publication 22 February 2016 Cite this article as: Hetzer R, Kaufmann F, Delmo Walter EM. Paediatric
More informationAcute heart failure: ECMO Cardiology & Vascular Medicine 2012
Acute heart failure: ECMO Cardiology & Vascular Medicine 2012 Lucia Jewbali cardiologist-intensivist 14 beds/8 ICU beds Acute coronary syndromes Heart failure/ Cardiogenic shock Post cardiotomy Heart
More informationAccepted Manuscript. Extracorporeal Membrane Oxygenation for Septic Shock: Heroic Futility? Francis D. Pagani, MD PhD
Accepted Manuscript Extracorporeal Membrane Oxygenation for Septic Shock: Heroic Futility? Francis D. Pagani, MD PhD PII: S0022-5223(18)31214-5 DOI: 10.1016/j.jtcvs.2018.04.076 Reference: YMTC 12949 To
More information3/23/2018. Complications of VAD Therapy: Arrhythmias. Disclosures. Agenda. I have no relevant disclosures
March 23, 2018 Complications of VAD Therapy: Arrhythmias Sandeep M. Jani, MD, MPH Associate Directory of Advanced Heart Failure and Population Health MedStar Heart and Vascular Institute - Baltimore Sandeep
More informationMechanical Circulatory Support: Reality and Dreams Experience of a Single Center
The Journal of The American Society of Extra-Corporeal Technology Mechanical Circulatory Support: Reality and Dreams Experience of a Single Center H.-H. Weitkemper, RN, ECCP; A. El-Banayosy, MD; L. Arusoglu,
More informationClinical Policy: Total Artificial Heart Reference Number: CP.MP.127
Clinical Policy: Reference Number: CP.MP.127 Effective Date: 12/16 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationExtracorporeal Membrane Oxygenation (ECMO)
Extracorporeal Membrane Oxygenation (ECMO) Policy Number: Original Effective Date: MM.12.006 05/16/2006 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2017 Section: Other/Miscellaneous
More informationMulti-Targeted Antithrombotic Therapy for Total Artificial Heart Device Patients
The Journal of ExtraCorporeal Technology Multi-Targeted Antithrombotic Therapy for Total Artificial Heart Device Patients Angeleah Ramirez, BS, MS, CCP; Jeffrey B. Riley, MHPE, CCP; Lyle D. Joyce, MD,
More informationEffective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature)
1 of 5 Policy #: 702 (PHL-702-05) Effective Date: 9/30/2004 Reviewed Date: 8/1/2016 Subject: TRANSFUSION GUIDELINES Approved by: Laboratory Director, Jerry Barker (electronic signature) Approved by: Laboratory
More informationAortic Insufficiency: How Often Does It Occur and When To Treat
Aortic Insufficiency: How Often Does It Occur and When To Treat Simon Maltais, MD PhD Vice-Chair of Clinical Practice Director of MCS Program Department of Cardiovascular Surgery Mayo Clinic, Rochester,
More information